Retinoids as chemopreventive agents

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 1, 2003, Pages 66-91

  Ralhan, Ranju ^a   Kaur, J ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cancer; Clinical trials; Precancer; RAR; Retinoids; Rexinoids

Indexed keywords

4 DIMETHYLAMINO 3' METHYLAZOBENZENE; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; 4 [7 ADAMANTYL 6 [(2 METHOXYETHOXY)METHOXY] 2 NAPHTHYL]BENZOIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; 6 [4 METHOXY 3 (1 METHYLCYCLOHEXYL)PHENYL] 2 NAPHTHOIC ACID; ANTINEOPLASTIC AGENT; BETA CAROTENE; BEXAROTENE; CD 2325; CD 336; CD 3369; CELL SURFACE RECEPTOR; ETRETIN; ETRETINATE; FENRETINIDE; ISOTRETINOIN; LGD 1550; MITOGEN ACTIVATED PROTEIN KINASE; NIK 333; PLACEBO; POLYPRENOIC ACID; PROTEIN KINASE B; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR; RETINOL; RETINOL PALMITATE; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BILE DUCT CARCINOMA; BONE DISEASE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; EYE DISEASE; GENETIC REGULATION; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HOMEOSTASIS; HUMAN; LIVER CANCER; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; MOUTH CANCER; NONHUMAN; PLEIOTROPY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN DISEASE; TERATOGENICITY; TISSUE SPECIFICITY;

EID: 0038147046     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (283)

1. Davies P, Lippman SM. Biologic basis of retinoid pharmacology: implications for cancer prevention and therapy. Adv Oncol 1996; 12: 2-10.
2. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998; 90: 1514-28.
3. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031-9.
4. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000; (Suppl) 130: S479-82.
5. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist 2000; 5:361-8.
6. Altucci L, Gronmneyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
7. Tamimi RM, Lagiou P, Adami HO, Trichopoulos D. Prospects for chemoprevention of cancer. J Intern Med 2002; 251: 286-300.
8. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35: 1332-8.
9. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980; 605: 33-91.
10. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of retinoids. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry and medicine, 2nd ed. New York, NY: Raven Press Ltd, 1994: 443-520.
11. Lotan R. Vitamin A analogs (retinoids) as biological response modifiers. Prog Clin Biol Res 1988; 259: 261-71.
12. Mangelsdorf D, Umesono K, Evans RM. The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine. New York, NY: Raven Press Ltd, 1994: 319-49.
13. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-54.
14. Nason-Burchenal K, Dmitrovsky E. The retinoids: cancer therapy and prevention mechanisms. In: Nau H, Blanner W, eds. Retinoids. The Biochemical and molecular basis of vitamin A and retinoid action. Handbook of experimental pharmacology. Berlin: Springer, 1999, 139: 301-22.
15. Hong WK, Itri LM. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine, 2nd ed. New York: Raven Press Ltd, 1994, 597-630.
16. Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E. Cyclin proteolysis as a retinoid cancer prevention mechanism. Ann NY Acad Sci 2001; 952: 13-22.
17. Hong WK, Sporn MB. Recent advances in chemo-prevention of cancer. Science 1997; 278: 1073-7.
18. Barnes MN, Grizzle WE, Grubbs CJ, Partridge EE. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 2002; 52: 216-25.
19. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Eng] J Med 1986; 315: 1501-5.
20. Meyskens FL Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-transretinoic acid: a randomized trial. J Natl Cancer Inst 1994; 86: 539-43.
21. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
22. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
23. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11: 1216-22.
24. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334: 1561-7.
25. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847-56.
26. The alpha-tocopherol, beta-carotene cancer prevention study group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
27. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
28. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
29. Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998; 10: 373-83.
30. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85: 403-14.
31. Pfahl M. Nuclear receptor/AP-1 interaction. Endocr Rev 1993; 14: 651-8.
32. Zhou XF, Shen XQ, Shemshedini L. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. Mol Endocrinol 1999; 13: 276-85.
33. Chen JY, Clifford J, Zusi C, et al. Two distinct actions of retinoid-receptor ligands. Nature 1996; 382: 819-22.
34. Perlmann T, Evans RM. Nuclear receptors in Sicily: all in the famiglia. Cell 1997; 90: 391-7.
35. Comic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992; 52: 3329-34.
36. Muindi J, Frankel SR, Miller WH Jr., et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 1992; 79: 299-303.
37. Ozpolat B, Lopez-Berestein G, Mehta K. ATRA(ouble) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 2001; 15: 107-22.
38. Mangersdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
39. Benoit G, Altucci L, Flexor M, et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J 1999; 18: 7011-8.
40. Benoit GR, Flexor M, Besancon F, et al. Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol Endocrinol 2001; 15: 1154-69.
41. Lala DS, Mukherjee R, Schulman IG, et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 1996; 383: 450-3
42. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
43. Perlmann T, Evans RM. Nuclear receptors in Sicily: all in the famiglia. Cell 1997; 90: 391-7.
44. Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 1998; 5: 11-9.
45. Matsushima-Nishiwaki R, Okuno M, Adachi S, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001; 61: 7675-82.
46. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 1984; 73: 1389-93.
47. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995; 207: 382-8.
48. Nemes Z Jr., Adany R, Balazs M, Boross P, Fesus L. Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis. J Biol Chem 1997; 272: 20577-83.
49. Oliverio S, Amendola A, Di Sano F, et al. Tissue transglutaminase-dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol Cell Biol 1997; 17: 6040-8.
50. Melino G, Annicchiarico-Petruzzelli M, Piredda L, et al. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994; 14: 6584-96.
51. Ou H, Haendeler J, Aebly MR, et al. Retinoic acid-induced tissue transglutaminase and apoptosis in vascular smooth muscle cells. Circ Res 2000; 87: 881-7.
52. Nagy L, Saydak M, Shipley N, et al. Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. J Biol Chem 1996; 271: 4355-65.
53. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58: 3163-72.
54. Verheijen MH, Wolthuis RM, Defize LH, den Hertog J, Bos JL. Interdependent action of RaIGEF and Erk in Ras-induced primitive endoderm differentiation of F9 embryonal carcinoma cells. Oncogene 1999; 18: 4435-9.
55. Moghal N, Neel BG. Integration of growth factor, extracellular matrix, and retinoid signals during bronchial epithelial cell differentiation. Mol Cell Biol 1998; 18: 6666-78.
56. Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 1997; 90: 97-107.
57. Bastien J, Adam-Stitah S, Riedl T, Egly JM, Chambon P, Rochette-Egly C. TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7. J Biol Chem 2000; 275: 21896-904.
58. Gianni M, Kopf E, Bastien J, et al. Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2. J Biol Chem 2002; 277: 24859-62.
59. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 893-901.
60. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-10.
61. Park HS, Kim MS, Huh SH, et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 2002; 277: 2573-8.
62. Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa WC. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 2001; 276: 30359-65.
63. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994; 14: 5-11.
64. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332: 1405-10.
65. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58: 479-84.
66. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56: 5566-70.
67. Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE. Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis 2002; 23: 447-56.
68. Sharp RM, Bello-DeOcampo D, Quader ST, Webber MM. N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention. Mutat Res 2001; 496: 163-70.
69. Vaccari M, Silingardi P, Argnani A, et al. In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res 2000; 20: 3059-66.
70. Hsieh T, Wu JM. Apoptosis and restriction of G(1)/S cell cycle by fenretinide in Burkitt's lymphoma mutu I cell line accessed with bcl-6 down- regulation. Biochem Biophys Res Commun 2000; 276: 1295-301.
71. Brodowicz T, Wiltschke C, Kandioler-Eckersberger D, et al. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br J Cancer 1999; 80: 1350-8.
72. Jinno H, Steiner MG, Mehta RG, Osborne MP, Telang NT. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. Carcinogenesis 1999; 20: 229-36.
73. Kitareewan S, Spinella MJ, Allopenna J, Reczek PR, Dmittovsky E. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway. Oncogene 1999; 18: 5747-55.
74. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036-41.
75. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 1191-8.
76. Fanjul AN, Delia D, Pierotti MA, et al. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996; 271: 22441-6.
77. Johanning GL, Cope MB, Wilborn T, Grubbs CJ, Lubet RA. Effect of high retinoid doses on RAR-beta mRNA expression in female B6D2F1 mice. Anticancer Res 2001; 21: 1691-5.
78. Webber MM, Bello-DeOcampo D, Quader S, Deocampo ND, Metcalfe WS, Sharp RM. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis 1999; 17: 255-63.
79. Lu XP, Fanjul A, Picard N, Shroot B, Pfahl M. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int J Cancer 1999; 80: 272-8.
80. Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997; 18: 943-8.
81. Moriwaki H, Muto Y, Ninomiya M, Kawai K, Suzuki Y, Seto T. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3'-methyl-N,N-dimethyl-4-aminoazobenzene. Gastroenterol Jpn 1988; 23: 546-52.
82. Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol 2001; 16: 1329-35.
83. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-7.
84. Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma, Clin Cancer Res 1997; 3: 727-31.
85. Kojima S, Ichinose A. Transglutaminase and apoptosis. Seikagaku 2000; 72: 198-202.
86. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-65.
87. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82.
88. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68: 67-108.
89. Dierov J, Sawaya BE, Prosniak M, Gartenhaus RB. Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell leukemia cells. Clin Cancer Res 1999; 5: 2540-7.
90. Langenfeld J, Lonardo F, Kiyokawa H, et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 1996; 13: 1983-90.
91. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 1997; 94: 12070-4.
92. Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst 1999; 91: 373-9.
93. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999; 274: 22013-8.
94. Quaia M, Zancai P, Cariati R, Rizzo S, Boiocchi M, Dolcetti R. Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes. Blood 2000; 96: 711-8.
95. Le Q, Dawson MI, Soprano DR, Soprano KJ. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene 2000; 19: 1457-65.
96. Jiang SY, Lin DY, Shyu RY, Reichert U, Yeh MY. The RARgamma selective agonist CD437 inhibits gastric cell growth through the mechanism of apoptosis. Cancer Lett 1999; 137: 217-25.
97. Wan H, Dawson MI, Hong WK, Lotan R. Overexpressed activated retinoid X receptors can mediate growth inhibitory effects of retinoids in human carcinoma cells. J Biol Chem 1998; 273: 26915-22.
98. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330: 1029-35.
99. Wu Q, Chen Z, Su W. Growth inhibition of gastric cancer cells by all-trans retinoic acid through arresting cell cycle progression. Chin Med J 2001; 114: 958-61.
100. Sueoka N, Lee HY, Walsh GL, Hong WK, Kurie JM. Posttranslational mechanisms contribute to the suppression of specific cyclin: CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. Cancer Res 1999; 59: 3838-44.
101. Smith HS. Tumor-suppressor genes in breast cancer progression. Cancer Treat Res 1994; 71: 79-96.
102. Kaiser A, Brembeck FH, Nicke B, Wiedenmann B, Riecken EO, Rosewicz S. All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5. J Biol Chem 1999; 274: 18925-31.
103. Sun SY, Wan H, Yue P, Hong WK, Lotan R. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000; 275: 17149-53.
104. Falk LA, De Benedetti F, Lohrey N, et al. Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. Blood 1991; 77: 1248-55.
105. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56: 1545-50.
106. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996; 271: 31723-8.
107. Zhang LX, Mills KJ, Dawson MI, Collins SJ, Jetten AM. Evidence for the involvement of retinolc acid receptor RAR alpha-dependent signaling pathway in the induction of tissue transglutaminase and apoptosis by retinoids. J Biol Chem 1995; 270: 6022-9.
108. Sun SY, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999; 59: 2829-33.
109. Griep AE, DeLuca HF. Decreased c-myc expression is an early event in retinoic acid-induced differentiation of F9 teratocarcinoma cells. Proc Natl Acad Sci USA 1986; 83: 5539-43.
110. Ozeki A, Tsukamoto I. Retinoic acid repressed the expression of c-fos and c-jun and induced apoptosis in regenerating rat liver after partial hepatectomy. Biochim Biophys Acta 1999; 1450: 308-19.
111. Kang HJ, Song MR, Lee SK, et al. Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Exp Cell Res 2000; 256: 545-54.
112. Kolla W, Weilhua X, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997; 272: 9742-8.
113. Sakaue M, Adachi H, Jetten AM. Post-transcriptional regulation of MyD118 and GADD45 in human lung carcinoma cells during 6-[3-(1-adamantyl)-4-hydro-xyphenyl]-2-naphthalene carboxylic acid-induced apoptosis. Mol Pharmacol 1999; 55: 668-76.
114. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res 1996; 16: 2415-9.
115. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells. Oncogene 1999; 18: 3894-901.
116. Li Y, Lin B, Agadir A, et al. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998; 18: 4719-31.
117. Dokmanovic M, Chang BD, Fang J, Roninson IB. Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes. Cancer Biol Ther 2002; 1: 24-7; discussion 28-30.
118. Glick AB, Flanders KC, Danielpour D, Yuspa SH, Sporn MB. Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul 1989; 1: 87-97.
119. Liaudet-Coopman ED, Wellstein A. Regulation of gene expression of a binding protein for fibroblast growth factors; by retinoic acid. J Biol Chem 1996; 271: 21303-8.
120. Liaudet-Coopman ED, Schulte AM, Cardillo M, Wellstein A. A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth. Biochem Biophys Res Commun 1996; 229: 930-7.
121. Xiao JH, Feng X, Di W, et al. Identification of heparin-binding EGF-like growth factor as a target in intercellular regulation of epidermal basal cell growth by suprabasal retinoic acid receptors. EMBO J 1999; 18: 1539-48.
122. Lowe WL Jr, Meyer T, Karpen CW, Lorentzen LR. Regulation of insulin-like growth factor I production in rat C6 glioma cells: possible role as an autocrine/paracrine growth factor. Endocrinology 1992; 130: 2683-91.
123. Fontana A Burrows-Mezu A, Clemmons DR, LeRoith D. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 1991; 128: 1115-22.
124. Schmid C, Schlapfer I, Waldvogel M, et al. Differential regulation of insulin-like growth factor binding protein (IGFBP)-2 mRNA in liver and bone cells by insulin and retinoic acid in vitro. FEBS Lett 1992; 303: 205-9.
125. Trechsel U, Evequoz V, Fleisch H. Stimulation of interleukin 1 and 3 production by retinoic acid in vitro. Biochem J 1985; 230: 339-44.
126. Dillehay DL, Walia AS, Lamon EW. Effects of retinoids on macrophage function and IL-1 activity. J Leukoc Biol 1988; 44: 353-60.
127. Matikainen S, Serkkola E, Hurme M. Retinoic acid enhances IL-1 beta expression in myeloid leukemia cells and in human monocytes. J Immunol 1991; 147: 162-7.
128. Carman JA, Hayes CE. Abnormal regulation of IFN-gamma secretion in vitamin A deficiency. J Immunol 1991; 147: 1247-52.
129. Widschwendter M, Daxenbichler G, Culig Z, et al. Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interfer-on-gamma in breast cancer cell lines. Int J Cancer 1997; 71: 497-504.
130. Matikainen S, Ronni T, Lehtonen A, et al. Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ 1997; 8: 687-98.
131. Guzhova I, Hultquist A, Cetinkaya C, Nilsson K, Pahlman S, Larsson LG. Interferon-gamma cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells. Int J Cancer 2001; 94: 97-108.
132. Bichler E, Daxenbichler G, Marth C. Vitamin A status and retinoid-binding proteins in carcinomas of the head and neck region. Oncology 1983; 40: 336-9.
133. Fex G, Wahlberg P, Biorklund A, Wennerberg J, Willen R. Studies of cellular retinol-binding protein (CRBP) in squamous-cell carcinomas of the head and neck region. Int J Cancer 1986; 37: 217-21.
134. Rumi G Jr, Matus Z, Toth G, et al. Changes of serum carotenoids in patients with esophageal, gastric, hepatocellular, pancreatic and colorectal cancer. J Physiol Paris 2001; 95: 239-42.
135. Sato R, Helzlsouer KJ, Alberg AJ, Hoffman SC, Norkus EP, Comstock GW. Prospective study of carotenoids, tocopherols, and retinoid concentrations and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 451-7.
136. Nagao T, Ikeda N, Warnakulasuriya S, et al. Serum antioxidant micronutrients and the risk of oral leukoplakia among Japanese. Oral Oncol 2000; 36: 466-70.
137. Guo X, Gudas LJ. Metabolism of all-trans-retinol in normal human cell strains and squamous cell carcinoma (SCC) lines from the oral cavity and skin: reduced esterification of retinol in SCC lines. Cancer Res 1998; 58: 166-76.
138. Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ. Enhanced turnover of all-trans-retinoic acid and increased formation of polar metabolites in head and neck squamous cell carcinoma lines compared with normal oral keratinocytes. Clin Cancer Res 2001; 7: 1017-25.
139. Duester G. Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis. Biochemistry 1996; 35: 12221-7.
140. Roberts ES, Vaz AD, Coon MJ. Role of isozymes of rabbit microsomal cytochrome P-450 in the metabolism of retinoic acid, retinol, and retinal. Mol Pharmacol 1992; 41: 427-33.
141. Raner GM, Vaz AD, Coon MJ. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral. Mol Pharmacol 1996; 49: 515-22.
142. Leo MA, Lieber CS. New pathway for retinol metabolism in liver microsomes. J Biol Chem 1985; 260: 5228-31.
143. Zhang QY, Raner G, Ding X, Dunbar D, Coon MJ, Kaminsky LS. Characterization of the cytochrome P450 CYP2J4: expression in rat small intestine and role in retinoic acid biotransformation from retinal. Arch Biochem Biophys 1998; 353: 257-64.
144. Blumberg B, Bolado J Jr., Derguini F, et al. Novel retinoic acid receptor ligands in Xenopus embryos. Proc Natl Acad Sci USA 1996; 93: 4873-8.
145. Pijnappel WW, Folkers GE, de Jonge WJ, et al. Metabolism to a response pathway selective retinoid ligand during axial pattern formation. Proc Natl Acad Sci USA 1998; 95:15424-9.
146. Rosecrans JA, Karan LD. Neurobehavioral mechanisms of nicotine action: role in the initiation and maintenance of tobacco dependence. J Subst Abuse Treat 1993; 10: 161-70.
147. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990; 87: 3294-8.
148. Chini B, Clementi F, Hukovic N, Sher E. Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines. Proc Natl Acad Sci USA 1992; 89: 1572-6.
149. Quik M, Chan J, Patrick J. alpha-Bungarotoxin blocks the nicotinic receptor mediated increase in cell number in a neuroendocrine cell line. Brain Res 1994; 655: 161-7.
150. Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 1998; 55: 1377-84.
151. Arredondo J, Nguyen VT, Chernyavsky Al, Jolkovsky DL, Pinkerton KE, Grando SA. A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest 2001; 81: 1653-68.
152. Chen GQ, Lin B, Dawson MI, Zhang XK. Nicotine modulates the effects of retinoids on growth inhibition and RAR beta expression in lung cancer cells. Int J Cancer 2002; 99: 171-8.
153. Lin F, Kolluri SK, Chen GQ, Zhang XK. Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor. J Biol Chem 2002; 277: 21414-22.
154. Lin B, Chen GQ, Xiao D, et al. Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 2000; 20: 957-70.
155. Ben-Shushan E, Sharir H, Pikarsky E, Bergman Y. A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor: retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells. Mol Cell Biol 1995; 15: 1034-48.
156. Zhang XK. Vitamin A and apoptosis in prostate cancer. Endocr Relat Cancer 2002; 9: 87-102.
157. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000; 289: 1159-64.
158. Wu Q, Dawson MI, Zheng Y, et al. Inhibition of transretinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 1997; 17: 6598-608.
159. Cote S, Sinnett D, Momparler RL. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 1998; 9: 743-50.
160. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000; 92: 1303-7.
161. Song S, Xu XC. Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem Biophys Res Commun 2001; 281: 872-7.
162. Osborne MR, Crosby NT. Benzopyrenes 1987; Cambridge University Press, Cambridge.
163. Jeng JH, Ho YS, Chan CP, et al. Areca nut extract upregulates prostaglandin production, cyclooxygenase-2mRNA and protein expression of human oral keratinocytes. Carcinogenesis 2000; 21: 1365-70.
164. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 over-expression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7: 861-7.
165. Mestre JR, Subbaramaiah K, Sacks PG, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997; 57: 2890-5.
166. Li M, Song S, Lippman SM, et al. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 2002; 21: 411-8.
167. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 1999; 96: 9827-32.
168. Jaffey P, Chan LN, Shao J, Schneider-Schaulies J, Chan TS. Retinoic acid inhibition of serum-induced c-fos transcription in a fibrosarcoma cell line. Cancer Res 1992; 52: 2384-8.
169. Yang-Yen HF, Zhang XK, Graupner G, et al. Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biol 1991; 3:1206-19.
170. Schule R, Rangarajan P, Yang N, et al. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci USA 1991; 88: 6092-6.
171. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85: 403-14.
172. Lin F, Xiao D, Kolluri SK, Zhang X. Unique anti-activator protein-1 activity of retinoic acid receptor beta. Cancer Res 2000; 60: 3271-80.
173. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of
174. van der Burg B, Slager-Davidov R, van der Leede BM, de Laat SW, van der Saag PT Differential regulation of AP1 activity by retinoic acid in hormone-dependent and -independent breast cancer cells. Mol Cell Endocrinol 1995; 112: 143-52.
175. Lee HY, Dawson MI, Walsh GL, et al. Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ 1996; 7: 997-1004.
176. Majerus MA, Bibollet-Ruche F, Telliez JB, Wasylyk B, Bailleul B. Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter. Nucleic Acids Res 1992; 20: 2699-703.
177. Pande P, Mathur M, Shukla NK, Ralhan R. Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas. J Pathol 1999; 189: 40-5.
178. Wasylyk C, Schlumberger SE, Criqui-Filipe P, Wasylyk B. Sp100 interacts with Ets-1 and stimulates its transcriptional activity. Mol Cell Biol 2002; 22: 2687-702.
179. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I. Expression of the Ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001; 14: 415-22.
180. Valter MM, Hugel A, Huang HJ, et al. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Fit-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 1999; 59: 5608-14.
181. Pande P, Soni S, Chakravarti N, Mathur M, Shukla NK, Ralhan R. Prognostic impact of Ets-1 overexpression in betel and tobacco related oral cancer. Cancer Detect Prev 2001; 25: 496-501.
182. Xu XC, Lotan R. Aberrant expression and function of retinoid receptors in cancer. In: Nau H, Blaner WS, eds. Retinoids-the biochemical and molecular basis of vitamin A and retinoid action. handbook of experimental pharmacology, Berlin: Springer-Verlag, 1999, Vol. 139, pp. 323-43.
183. Chakravarti N, Mathur M, Bahadur S, Shukla NK, Rochette-Egly C, Ralhan R. Expression of RARalpha and RARbeta in human oral potentially malignant and neoplastic lesions. Int J Cancer 2001; 91: 27-31.
184. Nakajima M, Lotan D, Baig MM, et al. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res 1989; 49: 1698-706.
185. Wood WR, Seftor EA, Lotan D, et al. Retinoic acid inhibits human melanoma tumor cell invasion. Anticancer Res 1990; 10: 423-32.
186. Clark SD, Kobayashi DK, Welgus HG. Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 1987; 80: 1280-8.
187. Zhu YK, Liu X, Ertl RF, et al. Retinoic acid attenuates cytokine-driven fibroblast degradation of extracellular matrix in three-dimensional culture. Am J Respir Cell Mol Biol 2001; 25: 620-7.
188. Frankenberger M, Hauck RW, Frankenberger B, et al. All trans-retinoic acid selectively down-regulates matrix metalloproteinase-9 (MMP-9) and up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) in human bronchoalveolar lavage cells. Mol Med 2001; 7: 263-70.
189. Adachi Y, Itoh F, Yamamoto H, et al. Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol 2001; 22: 247-53.
190. Igarashi T, Abe M, Oikawa M, Nukiwa T, Sato Y. Retinoic acids repress the expression of ETS-1 in endothelial cells. Tohoku J Exp Med 2001; 194: 35-43.
191. Tsang KJ, Crowe DL. Retinoic acid and extracellular matrix inhibition of matrix metalloproteinase 9 expression is mediated by the mitogen activated protein kinase pathway. Int J Oncol 2001; 18: 369-74.
192. Luscher B, Mitchell PJ, Williams T, Tjian R. Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev 1989; 3: 1507-17.
193. Hosler BA, LaRosa GJ, Grippo JF, Gudas LJ. Expression of REX-1, a gene containing zinc finger motifs, is rapidly reduced by retinoic acid in F9 teratocarcinoma cells. Mol Cell Biol 1989; 9: 5623-9.
194. Edwards SA, Darland T, Sosnowski R, Samuels M, Adamson ED. The transcription factor, Egr-1, is rapidly modulated in response to retinoic acid in P19 embryonal carcinoma cells. Dev Biol 1991; 148: 165-73.
195. Suva LJ, Harm SC, Gardner RM, Thiede MA. In vivo regulation of Zif268 messenger RNA expression by 17 beta-estradiol in the rat uterus. Mol Endocrinol 1991; 5: 829-35.
196. Cillo C, Faiella A, Cantile M, Boncinelli E. Homeobox genes and cancer. Exp Cell Res 1999; 248: 1-9.
197. Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in breast carcinomas. Anticancer Res 2000; 20: 3281-6.
198. Raman V, Martensen SA, Reisman D, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000; 405: 974-8.
199. Folberg A, Nagy Kovacs E, Luo J, Giguere V, Featherstone MS. RARbeta mediates the response of Hoxd4 and Hoxb4 to exogenous retinoic acid. Dev Dyn 1999; 215: 96-107.
200. Kim C, Nielsen HC. Hoxa-5 in mouse developing lung: cell-specific expression and retinoic acid regulation. Am J Physiol Lung Cell Mol Physiol 2000; 279: L863-71.
201. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
202. Altucci L, Gronemeyer H. Decryption of the retinoid death code in leukemia. J Clin Immunol 2002; 22: 117-23.
203. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680-6.
204. Bradbury J. TRAIL leads to apoptosis in acute promyelocytic leukaemia. Lancet 2001; 357: 1770.
205. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60: 7149-55.
206. Sun SY, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000; 19: 4513-22.
207. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-92.
208. Pande P, Mathur M, Shukla NK, Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol 1998; 34: 396-403.
209. Ravi D, Nalinakumari KR, Rajaram RS, Nair MK, Pillai MR. Expression of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Cancer Lett 1996; 105: 139-46.
210. Kaur J, Srivastava A, Ralhan R. Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous-cell carcinoma in India. Int J Cancer 1994; 58: 340-5.
211. Baral R, Patnaik S, Das BR. Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci 1998; 106: 907-13.
212. Kuttan NA, Rosin MP, Ambika K, Priddy RW, Bhakthan NM, Zhang L. High prevalence of expression of p53 oncoprotein in oral carcinomas from India associated with betel and tobacco chewing. Eur J Cancer B Oral Oncol 1995; 31 B: 169-73.
213. Kaur J, Srivastava A, Ralhan R. Prognostic significance of p53 protein overexpression in betel- and tobacco-related oral oncogenesis. Int J Cancer 1998; 79: 370-5.
214. Pande P, Soni S, Kaur J, et al. Prognostic factors in betel and tobacco related oral cancer. Oral Oncol 2002; 38: 491-9.
215. Zhang W, Rashid A, Wu H, Xu XC. Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues. J Cancer Res Clin Oncol 2001; 127: 237-42.
216. Charkravarti N, Mathur M, Bahadur S, Shukla NK, Ralhan R. Retinoic acid receptor-alpha as a prognostic indicator in oral squamous cell carcinoma. Int J Cancer 2002 (in Press).
217. Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3: 875-80.
218. Hayashi K, Yokozaki H, Naka K, Yasui W, Lotan R, Tahara E. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J Cancer Res 2001; 92: 42-50.
219. Cheung B, Hocker JE, Smith SA, Norris MD, Haber M, Marshall GM. Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene 1998; 17: 751-9.
220. Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, Spinella MJ. Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene 2001; 20: 2559-69.
221. D'Ambrosio SM, Gibson-D'Ambrosio RE, Wani G, et al. Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res 2001; 21: 3229-35.
222. Nakashima T, Sun SY, Lotan R, et al. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. Laryngoscope 2001; 111: 1459-64.
223. Zhang D, Vuocolo S, Masciullo V, et al. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 2001; 20: 7935-44.
224. Hayashi K, Yokozaki H, Naka K, et al. Effect of 9-cisretinoic acid on oral squamous cell carcinoma cell lines. Cancer Lett 2000; 151: 199-208.
225. Shao ZM, Dawson MI, Li XS, et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995; 11: 493-504.
226. Lavelle D, Chen YH, Hankewych M, Desimone J. Inhibition of myeloma cell growth by all-trans retinoic acid is associated with upregulation of p21WAF1 and dephosphorylation of the retinoblastoma protein. Leuk Lymphoma 1999; 35: 261-8.
227. Liang JY, Fontana JA, Rao JN, et al. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate 1999; 38: 228-36.
228. Choi K, Frommel TO, Stern RK, et al. Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci USA 1991; 88: 7386-90.
229. Stromskaya TP, Rybalkina EY, Shtil AA, Zabotina TN, Filippova NA, Stavrovskaya AA. Influence of exogenous RAR alpha gene on MDR1 expression and P-glycoprotein function in human and rodent cell lines. Br J Cancer 1998; 77: 1718-25.
230. Jain V, Das SN, Luthra K, Shukla NK, Ralhan R. Differential expression of multidrug resistance gene product, P-glycoprotein, in normal, dysplastic and malignant oral mucosa in India. Int J Cancer 1997; 74: 128-33.
231. Ralhan R, Swain RK, Agarwal S, et al. P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 1999; 84: 80-5.
232. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997; 94: 11037-42.
233. Mathieu MC, Lapierre I, Brault K, Raymond M. Aromatic hydrocarbon receptor (AhR).AhR nuclear translocator- and p53-mediated induction of the murine multidrug resistance mdr1 gene by 3-methylcholanthrene and benzo(a)pyrene in hepatoma cells. J Biol Chem 2001; 276: 4819-27.
234. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997; 14: 929-35.
235. Ralhan R, Sandhya A, Meera M, Bohdan W, Nootan SK. Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer. Am J Pathol 2000; 157: 587-96.
236. Kelloff GJ, Boone CW, Crowell JA, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 1996; 26: 1-28.
237. Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine, second edition. New York, NY: Raven Press Ltd., 1994; 573-95.
238. Reddel RR, Ke Y, Gerwin BI, et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1988; 48: 1904-9.
239. Dejean A, Bougueleret L, Grzeschik KH, Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 1986; 322: 70-2.
240. Brand N, Petkovich M, Krust A, et al. Identification of a second human retinoic acid receptor. Nature 1988; 332: 850-3.
241. Kok K, Osinga J, Carritt B, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987; 330: 578-81.
242. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble vitamin A. J Exp Med 1925; 42: 753-7.
243. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12: 851-73.
244. Boisnic S, Branchet MC, Pascal F, Ben Slama L, Rostin M, Szpirglas H. Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa. A clinical evaluation. Ann Dermatol Venereol 1994; 121: 459-63.
245. Branchet MC, Boisnic S, Pascal F, Ben Slama L, Rostin M, Szpirglas H. Topical tretinoin in the treatment of lichen planus and leukoplakia of the oral mucosa. A biochemical evaluation of the keratinization. Ann Dermatol Venereol 1994; 121: 464-9.
246. Femiano F, Gombos F, Scully C, Battista C, Belnome G, Esposito V. Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin. Int J Oral Maxillofac Surg 2001; 30: 402-6.
247. Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol 1990; 126: 494-9.
248. Halpern AC, Schuchter LM, Elder DE, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 1994; 12: 1028-35.
249. Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S. Effect of topical tretinoin under occlusion on atypical nevi. Melanoma Res 1998; 8: 539-48.
250. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59: 714-9.
251. Toma S, Mangiante PE, Margarino G, Nicolo G, Palumbo R. Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia. Eur J Cancer B Oral Oncol 1992; 2813: 121-3.
252. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
253. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328: 15-20.
254. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2: 1787-93.
255. Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3: 875-80.
256. Beenken SW, Sellers MT, Huang P, et al. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head Neck 1999; 21: 566-73.
257. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6: 1702-10.
258. Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19: 715-8.
259. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12: 937-45.
260. Chiesa F, Tradati N, Marazza M, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993; 17F: 255-61.
261. Tradati N, Chiesa F, Rossi N, et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994; 76: 109-11.
262. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6: 2973-9.
263. Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001; 19: 1664-70.
264. Weiss HL, Urban DA, Grizzle WE, et al. Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer. Urology 2001; 57: 220-3.
265. Omenn GS, Goodman GE, Thomquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88: 1550-9.
266. Omenn GS, Goodman G, Thornquist M, et al. Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and as bestos-exposed workers. IARC Sci Publ 1996; 136: 67-85.
267. Albanes D, Heinonen OP, Taylor PR, et al. Alphatocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, betacarotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88: 1560-70.
268. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-4.
269. Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28: 284-90.
270. Miller WH Jr, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-8.
271. Collins SJ, Robertson KA, Mueller L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol 1990; 10: 2154-63.
272. Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS, Dmitrovsky E. Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene 1998; 16: 3471-80.
273. Houle B, Rochette-Egly C, Bradley WE. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc Natl Acad Sci USA 1993; 90: 985-9.
274. Ahn MJ, Langenfeld J, Moasser MM, Rusch V, Dmitrovsky E. Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors. Oncogene 1995; 11: 2357-64.
275. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
276. Li JY, Taylor PR, Li B, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993; 85: 1492-8.
277. Wang GQ, Dawsey SM, Li JY, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 1994; 3: 161-6.
278. Ruidi C, Aihua D, Peiyu B, et al. Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. J Cell Biochem Suppl 1997; 28-29: 140-3.
279. Chen RD, Ding AH, Han R. A study on chemoprevention of retinamide II from cervical precancerous lesions. Zhonghua Yu Fang Yi Xue Za Zhi 1994; 28: 75-7.
280. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
281. Langston AW, Thompson JR, Gudas LJ. Retinoic acid-responsive enhancers located 3' of the Hox A and Hox B homeobox gene clusters. Functional analysis. J Biol Chem 1997; 272: 2167-75.
282. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998; 58: 5551-8.
283. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999; 59: 14-8.